Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, et al.
The Lancet (2019) Vol. 394, Iss. 10193, pp. 131-138
Closed Access | Times Cited: 527

Showing 1-25 of 527 citing articles:

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, et al.
The Lancet (2019) Vol. 394, Iss. 10193, pp. 121-130
Closed Access | Times Cited: 2256
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Søren Lund Kristensen, Rasmus Rørth, Pardeep S. Jhund, et al.
The Lancet Diabetes & Endocrinology (2019) Vol. 7, Iss. 10, pp. 776-785
Open Access | Times Cited: 1291
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Molecular Metabolism (2020) Vol. 46, pp. 101102-101102
Open Access | Times Cited: 992
KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Ian H. de Boer, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2020) Vol. 98, Iss. 4, pp. S1-S115
Open Access | Times Cited: 962
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Naveed Sattar, Matthew M.Y. Lee, Søren Lund Kristensen, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 10, pp. 653-662
Open Access | Times Cited: 947
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Peter Rossing, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2022) Vol. 102, Iss. 5, pp. S1-S127
Open Access | Times Cited: 714
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Hertzel C. Gerstein, Naveed Sattar, Julio Rosenstock, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 10, pp. 896-907
Open Access | Times Cited: 529
Innate immunity in diabetic kidney disease
Sydney C.W. Tang, Wai Han Yiu
Nature Reviews Nephrology (2020) Vol. 16, Iss. 4, pp. 206-222
Closed Access | Times Cited: 400
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Antonino Di Pino, Ralph A. DeFronzo
Endocrine Reviews (2019) Vol. 40, Iss. 6, pp. 1447-1467
Open Access | Times Cited: 349
Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
Matthew Capehorn, Andrei‐Mircea Catarig, Julie Kjærulff Furberg, et al.
Diabetes & Metabolism (2019) Vol. 46, Iss. 2, pp. 100-109
Closed Access | Times Cited: 306
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Yiwen Li, Yanfei Liu, Shiwei Liu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 257
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Michael A. Nauck, Jakob Wefers, Juris J. Meier
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 8, pp. 525-544
Closed Access | Times Cited: 207
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Michael A. Nauck, Juris J. Meier
European Journal of Endocrinology (2019) Vol. 181, Iss. 6, pp. R211-R234
Open Access | Times Cited: 199
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design
Donna H. Ryan, Ildiko Lingvay, Helen M. Colhoun, et al.
American Heart Journal (2020) Vol. 229, pp. 61-69
Open Access | Times Cited: 197
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 187
Pharmacological treatment of hyperglycemia in type 2 diabetes
Simeon I. Taylor, Zhinous Shahidzadeh Yazdi, Amber L. Beitelshees
Journal of Clinical Investigation (2021) Vol. 131, Iss. 2
Open Access | Times Cited: 183
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
Hiddo J.L. Heerspink, Naveed Sattar, Imre Pávó, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 11, pp. 774-785
Open Access | Times Cited: 164
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
Peter Rossing, Florian M.M. Baeres, George L. Bakris, et al.
Nephrology Dialysis Transplantation (2023) Vol. 38, Iss. 9, pp. 2041-2051
Open Access | Times Cited: 154
GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
Riccardo Nevola, Raffaella Epifani, Simona Imbriani, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1703-1703
Open Access | Times Cited: 134
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Rola Hammoud, Daniel J. Drucker
Nature Reviews Endocrinology (2022) Vol. 19, Iss. 4, pp. 201-216
Closed Access | Times Cited: 130
Should metformin remain the first-line therapy for treatment of type 2 diabetes?
Chelsea Baker, Cimmaron Retzik-Stahr, Vatsala Singh, et al.
Therapeutic Advances in Endocrinology and Metabolism (2021) Vol. 12
Open Access | Times Cited: 116
Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
Takayuki Yamada, Mako Wakabayashi, Abhinav Bhalla, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 112
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
Peter Rossing, Gerasimos Filippatos, Rajiv Agarwal, et al.
Kidney International Reports (2021) Vol. 7, Iss. 1, pp. 36-45
Open Access | Times Cited: 110
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo
Katherine R. Tuttle, Heidrun Bosch‐Traberg, David Z.I. Cherney, et al.
Kidney International (2023) Vol. 103, Iss. 4, pp. 772-781
Open Access | Times Cited: 76
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Helen M. Colhoun, Ildiko Lingvay, Paul Brown, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 2058-2066
Open Access | Times Cited: 66
Page 1 - Next Page

Scroll to top